Comparative Pharmacology
Head-to-head clinical analysis: LATANOPROST versus ZIOPTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATANOPROST versus ZIOPTAN.
LATANOPROST vs ZIOPTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that acts as a selective FP receptor agonist. It increases uveoscleral outflow of aqueous humor by binding to prostanoid FP receptors in the ciliary muscle, leading to matrix metalloproteinase activation and remodeling of the extracellular matrix, thereby reducing intraocular pressure.
ZIOPTAN (tafluprost) is a prostaglandin analog that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
Instill one drop (1.5 mcg) of 0.005% ophthalmic solution into the affected eye(s) once daily in the evening.
250 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateLatanoprost + Unoprostone
"Latanoprost may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateLatanoprost + Hydrochlorothiazide
"Latanoprost may increase the hypotensive activities of Hydrochlorothiazide."
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
Terminal half-life of latanoprost acid is 17 minutes (0.28 hours) systemically; clinically, intraocular pressure reduction persists for 24 hours due to prolonged receptor binding.
Terminal elimination half-life is approximately 2.8 to 4.5 hours in patients with normal renal function; no clinically significant accumulation occurs with twice-daily dosing.
Renal: 88% (metabolites); fecal: 6% (metabolites); unchanged latanoprost is not excreted renally.
Primarily renal excretion of unchanged drug (approximately 70-80% of an administered dose recovered in urine over 48 hours); biliary/fecal excretion accounts for 13% to 20% as parent drug and metabolites.
Category A/B
Category C
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."